NasdaqHealth CareBiological Products, (No Diagnostic Substances)SOLANA BEACH, CA

LENZ Therapeutics, Inc. LENZ

Ask your AI

Estimated market cap $129.77M31.42M shares, shares as of Oct 28, 2026CIK 1815776

Insider trades, 12 mo

3 buys · 5 sells

$9.40M sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

61.0% of shares · 32 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in LENZ Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 3, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in LENZ Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

8 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Oct 29, 2026. Insiders have two business days to file.

Recent insider trades

Ra Capital Management, L.P. 10% owner	Oct 29 Form 4 ↗	Sale	−$360.1K 107,170 sh @ $3.36	+20.3%
Ra Capital Management, L.P. 10% owner	Oct 29 Form 4 ↗	Sale	−$1.5M 451,998 sh @ $3.36	+20.3%
Ra Capital Management, L.P. 10% owner	Oct 29 Form 4 ↗	Sale	−$7.3M 2.16M sh @ $3.36	+20.3%
Jeffrey P. George Director	Mar 27 Form 4 ↗	Buy	+$49.9K 5,592 sh @ $8.92	-69.8%
Evert B. Schimmelpennink President, CEO and Secretary, Director	Mar 27 Form 4 ↗	Buy	+$251.4K 28,089 sh @ $8.95	-69.8%

All LENZ insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

19.15M shares

84 funds report LENZ. Values checked against market prices.

Funds report more than 100% of shares (Q2 2026)

145 funds hold the stock.

Q3 2026: 61% · 5,560 of ~8,900 funds reported so far

Q2 202587%
Q3 202593%
Q4 2025>100%
Q1 2026>100%
Q2 2026>100%
Q3 2026 (so far)61%

Q3 2026. 15 new, 32 added to, 21 trimmed, 76 exited since Q2 2026.

Top 13F holders
#
1	Alpha Wave Global, LP 13F ↗	3.61M	$13.9M	unchanged
2	BlackRock, Inc. 13F ↗	3.44M	$13.2M	+50.0%
3	Versant Venture Management, LLC 13F ↗	2.66M	$10.2M	unchanged
4	Vanguard Capital Management LLC 13F ↗	1.10M	$4.2M	unchanged
5	Squarepoint Ops LLC 13F ↗	966,920	$3.7M	-44.7%
6	Blue Owl Capital Holdings LP 13F ↗	781,722	$3.0M	+3.3%
7	C WorldWide Group Holding A/S 13F ↗	700,000	$2.7M	unchanged
8	FMR LLC 13F ↗	613,374	$2.4M	-82.8%
9	Primecap Management Co 13F ↗	472,200	$1.8M	unchanged
10	Geode Capital Management, LLC 13F ↗	434,515	$1.7M	-23.0%

One of these funds reports its values in thousands of dollars; its figures are shown in dollars.

Download CSV Every fund that holds LENZ, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What LENZ Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What LENZ Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q1 2024	55	—	16.29M	$363.3M
Q2 2024	65	+10	18.92M	$327.1M
Q3 2024	78	+13	18.74M	$444.9M
Q4 2024	94	+16	19.86M	$573.2M
Q1 2025	105	+11	21.07M	$541.8M
Q2 2025	113	+8	24.77M	$726.4M
Q3 2025	166	+53	29.15M	$1.4B
Q4 2025	163	-3	35.07M	$561.6M
Q1 2026	146	-17	33.15M	$303.4M
Q2 2026	145	-1	34.73M	$197.3M
Q3 2026	84	-61	19.15M	$73.5M

Each point is a quarter-end, from Q1 2024 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (52635N103). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2024) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes12 in 12 mo 8-K events1 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 1 in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record IPO history3 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: LENZ Therapeutics, Inc.
Address: 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA 92075
Phone: 858-925-7000
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: DE
Listed as: LENZ (Nasdaq)
Former names: Graphite Bio, Inc. (until 2024)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$4.13+$0.04 (+0.98%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $3.01 · High $4.29Nov 13, 2026

Aug 13, 2026Low $3.01 · High $5.96Nov 13, 2026

Nov 13, 2025Low $3.01 · High $31.94Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.